Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients

Experimental and Clinical Transplantation

Volumn 6, Issue 2, 2008, Pages 149-154

  Pajand, Omid ^a   Ziyaeyan, M ^b   Mousavi, S A ^c   Fatolahzadeh, B ^a   Hojabri, Z ^a   Bahador, A ^a   Abdossamadi, Z ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antigenemia; Hematopoietic cell transplantation; Human cytomegalovirus; PCR; Viral load

Indexed keywords

CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; METHOTREXATE; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTERMETHOD COMPARISON; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 52249122879     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Meijer E, Boland GJ, Verdonck LF. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. ClinMicrobiol Rev. 2003;16(4):647-657.
2. Stocchi R,Ward KN, Fanin R, BaccaraniM, Apperley JF.Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica. 1999;84(1):71-79.
3. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78-83.
4. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324(15):1005-1011.
5. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325(23):1601-1607.
6. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneicmarrow transplantation: a randomized double-blind study. Blood. 1996;88(10):4063-4071.
7. Dankner WM, McCutchan JA, Richman DD, Hirata K, Spector SA. Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. J Infect Dis. 1990;161(1):31-36.
8. Gerna G, Zipeto D, Percivalle E, et al. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J Infect Dis. 1992;166(6):1236-1244.
9. Saltzman RL, Quirk MR, Jordan MC. High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest. 1992;90(5):1832-1838.
10. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol. 2002;40(3):746-752.
11. Machida U, KamiM, Fukui T, et al. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J Clin Microbiol. 2000;38(7):2536-2542.
12. Cortez KJ, Fischer SH, Fahle GA, et al. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis. 2003;188(7):967-972.
13. Weinberg A, Schissel D, Giller R. Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients. J Clin Microbiol. 2002;40(11):4203-4206.
14. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis. 1999;28(3):618-623.
15. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159-1164.
16. Ziyaeyan M, Sabahi F, Alborzi A, et al. Diagnosis and monitoring of human cytomegalovirus infection in bone marrow transplant recipients by quantitative competitive PCR. Exp Clin Transplant. 2006;4(1):470-474.
17. Ksouri H, Eljed H, Greco A, et al. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation. Transpl Infect Dis. 2007;9(1):16-21.
18. Schäfer P, Tenschert W, Cremaschi L, Gutensohn K, Laufs R. Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR. J Clin Microbiol. 1998;36(4):1008-1014.
19. Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation. 2002;73(6):968-973.
20. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355(9220):2032-2036.
21. Kalpoe JS, Kroes AC, de Jong MD, et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol. 2004 Apr;42(4):1498-1504. Erratum in: J Clin Microbiol. 2004;42(10):4917.
22. Ikewaki J, Ohtsuka E, Satou T, et al. Real-time PCR assays based on distinct genomic regions for cytomegalovirus reactivation following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35(4):403-410.
23. Maeda Y, Teshima T, Yamada M, et al. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Br J Haematol. 1999;105(1):295-302.
24. Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;25(7):765-769.